Details for Patent: 4,659,516
✉ Email this page to a colleague
Summary for Patent: 4,659,516
| Title: | Steroid derivatives |
| Abstract: | A steroid derivative of the formula: wherein ST is a 7.alpha.-linked steroid nucleus of the general formula: ##STR1## wherein the double bond(s) between carbon atoms 6 and 7 and/or carbon atoms 8 and 9 are optional; wherein the aromatic ring A may optionally bear one or two halogen or alkyl substituents; wherein R.sup.3 is hydrogen, alkyl, or acyl; wherein R.sup.16 is hydrogen, alkyl or hydroxy; wherein either R.sup.17 is hydroxy or acyloxy and R.sup.27 is hydrogen, alkyl, alkenyl or alkynyl, or R.sup.17 and R.sup.27 together form oxo (.dbd.O); wherein R.sup.18 is alkyl; wherein A is alkylene, alkenylene or alkynylene optionally fluorinated and optionally interrupted by --O--, --S--, --SO--, --SO.sub.2 --, --CO--, --NR--, --NRCO--, --CONR--, --COO--, --OCO-- or phenylene, wherein R is hydrogen or alkyl; wherein R.sup.1 is hydrogen, alkyl, alkenyl, cycloalkyl, halogenoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl, arylalkyl, or dialkylaminoalkyl, or R.sup.1 is joined to R.sup.2 as defined below; and wherein X is --CONR.sup.2 --, --CSNR.sup.2 --, --NR.sup.12 CO--, --NR.sup.12 CS--, --NR.sup.12 CONR.sup.2 --, ##STR2## --SO.sub.2 NR.sup.2 -- or --CO--; or, when R.sup.1 is not hydrogen, is --O--, --NR.sup.2 --, --(NO)R.sup.2 --, --(PO)R.sup.2 --, --NR.sup.12 COO--; --NR.sup.12 SO.sub.2 --, --S--, --SO-- or --SO.sub.2 --; wherein R.sup.2 is hydrogen or alkyl or R.sup.1 and R.sup.2 together form alkylene or halogenoalkylene; wherein R.sup.12 is hydrogen or alkyl and wherein R.sup.22 is hydrogen, cyano or nitro; or a salt thereof when appropriate. |
| Inventor(s): | Bowler; Jean (Sandbach, GB), Tait; Brian S. (Macclesfield, GB) |
| Assignee: | Imperial Chemical Industries PLC (London, GB2) |
| Application Number: | 06/656,466 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Dosage form; Use; |
Drugs Protected by US Patent 4,659,516
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 4,659,516
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 8327256 | Oct 12, 1983 |
International Family Members for US Patent 4,659,516
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 35814 | ⤷ Try a Trial | |||
| Germany | 122004000011 | ⤷ Try a Trial | |||
| Germany | 3472792 | ⤷ Try a Trial | |||
| European Patent Office | 0138504 | ⤷ Try a Trial | SPC/GB04/009 | United Kingdom | ⤷ Try a Trial |
| European Patent Office | 0138504 | ⤷ Try a Trial | 91068 | Luxembourg | ⤷ Try a Trial |
| European Patent Office | 0138504 | ⤷ Try a Trial | 300158 | Netherlands | ⤷ Try a Trial |
| European Patent Office | 0138504 | ⤷ Try a Trial | 2004C/004 | Belgium | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
